RiiQ™ used in RSV vaccine trial to demonstrate effectiveness

The NEMJ has published a trial by Janssen; Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults. The ‘CYPRESS’ trial was a double-blind, placebo-controlled, phase 2b, proof-of-concept trial, at 40 centers in the United States. The RiiQ™ contributed to case definitions and provision of an overall assessment of efficacy. The vaccine was immunogenic and prevented RSV-mediated lower respiratory tract disease.